JP2022028918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022028918A5 JP2022028918A5 JP2021196080A JP2021196080A JP2022028918A5 JP 2022028918 A5 JP2022028918 A5 JP 2022028918A5 JP 2021196080 A JP2021196080 A JP 2021196080A JP 2021196080 A JP2021196080 A JP 2021196080A JP 2022028918 A5 JP2022028918 A5 JP 2022028918A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ror1
- biological sample
- antibody
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290337P | 2016-02-02 | 2016-02-02 | |
| US62/290,337 | 2016-02-02 | ||
| US201662324876P | 2016-04-19 | 2016-04-19 | |
| US62/324,876 | 2016-04-19 | ||
| JP2018539977A JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
| PCT/US2017/016300 WO2017136607A1 (en) | 2016-02-02 | 2017-02-02 | Anti-ror1 antibodies and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539977A Division JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022028918A JP2022028918A (ja) | 2022-02-16 |
| JP2022028918A5 true JP2022028918A5 (enExample) | 2022-06-23 |
Family
ID=58054529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539977A Active JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
| JP2021196080A Pending JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539977A Active JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10968275B2 (enExample) |
| EP (2) | EP3411408B1 (enExample) |
| JP (2) | JP7029401B2 (enExample) |
| CN (1) | CN108699149B (enExample) |
| AU (1) | AU2017213844A1 (enExample) |
| CA (1) | CA3012827A1 (enExample) |
| ES (1) | ES2903228T3 (enExample) |
| MX (1) | MX2018009011A (enExample) |
| WO (1) | WO2017136607A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103442A1 (es) | 2015-01-16 | 2017-05-10 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 |
| AU2016345681A1 (en) | 2015-10-30 | 2018-05-10 | Nbe-Therapeutics Ag | Anti-ROR1 antibodies |
| EP3405496B1 (en) | 2016-01-20 | 2023-10-25 | University of Florida Research Foundation, Incorporated | Ror1 antibody compositions and related methods |
| MX2018009011A (es) | 2016-02-02 | 2018-11-19 | Hutchinson Fred Cancer Res | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| EP3936523A4 (en) * | 2019-01-08 | 2022-09-07 | Shenzhen University | DETECTION OF ANTIBODIES AGAINST MALIGNANT TUMOR CELLS AND THEIR USES |
| CA3123303A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| US12545716B2 (en) | 2021-07-19 | 2026-02-10 | Immunome, Inc. | Immunoconjugates and methods |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| WO2023186100A1 (zh) * | 2022-04-02 | 2023-10-05 | 山东先声生物制药有限公司 | 抗ror1的抗体及其用途 |
| AU2023313641A1 (en) * | 2022-07-26 | 2025-03-13 | Aimed Bio Inc. | Anti-ror1 antibody and use thereof |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| JP2026500705A (ja) * | 2022-12-27 | 2026-01-08 | 上海医藥集團生物治療技術有限公司 | Ｒｏｒ１を標的とする抗原結合タンパク質 |
| CN115894691B (zh) * | 2022-12-27 | 2026-03-03 | 上海医药集团生物治疗技术有限公司 | 靶向ror1的抗原结合蛋白 |
| CN116183472B (zh) * | 2023-04-25 | 2023-08-18 | 上海益诺思生物技术股份有限公司 | Cba法检测非人类灵长类动物细胞因子的验证方法 |
| CN121443642A (zh) * | 2023-07-04 | 2026-01-30 | 天境生物科技(上海)有限公司 | 抗ror1抗体及其用途 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA114536A (en) | 1908-09-18 | 1908-10-13 | Adolphe Chalas | Nickel recovering process |
| CA138293A (en) | 1911-11-06 | 1912-02-06 | Charles E. Archie | Variable speed gearing |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| WO2003085093A2 (en) | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| US20050009136A1 (en) | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
| EP2060270A3 (en) | 2003-10-16 | 2009-12-09 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| EP1786463A4 (en) | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | ANTIBODY AGAINST NOGO RECEPTOR |
| CA2730201C (en) | 2008-07-10 | 2019-02-05 | Toray Industries, Inc. | Anti-cd179b antibody |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| AU2010238723A1 (en) | 2009-04-23 | 2011-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| US9163258B2 (en) | 2010-07-23 | 2015-10-20 | Fred Hutchinson Cancer Research Center | Method for the treatment of obesity |
| EP3219731A1 (en) | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| CA2818992C (en) | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2741770A4 (en) | 2011-08-09 | 2014-12-31 | Athera Biotechnologies Ab | ANTIBODY BINDING TO PHOSPHORYLCHOLIN (PC) AND / OR PC CONJUGATES |
| ES2806146T3 (es) | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
| PL3824905T3 (pl) | 2012-08-20 | 2025-05-05 | Fred Hutchinson Cancer Center | Sposób i kompozycje do immunoterapii komórkowej |
| CA2881966C (en) | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| HK1220614A1 (zh) | 2013-03-10 | 2017-05-12 | Baylor College Of Medicine | 耐化疗免疫细胞 |
| ES2715413T3 (es) | 2014-07-29 | 2019-06-04 | Cellectis | Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer |
| MX389823B (es) | 2014-10-27 | 2025-03-20 | Fred Hutchinson Cancer Center | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
| AR103442A1 (es) | 2015-01-16 | 2017-05-10 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 |
| WO2016187216A1 (en) | 2015-05-18 | 2016-11-24 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
| MX2018009011A (es) | 2016-02-02 | 2018-11-19 | Hutchinson Fred Cancer Res | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. |
| MX2018014911A (es) | 2016-06-06 | 2019-08-12 | Juno Therapeutics Inc | Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas. |
-
2017
- 2017-02-02 MX MX2018009011A patent/MX2018009011A/es unknown
- 2017-02-02 JP JP2018539977A patent/JP7029401B2/ja active Active
- 2017-02-02 AU AU2017213844A patent/AU2017213844A1/en not_active Abandoned
- 2017-02-02 CA CA3012827A patent/CA3012827A1/en active Pending
- 2017-02-02 US US16/074,737 patent/US10968275B2/en active Active
- 2017-02-02 ES ES17705745T patent/ES2903228T3/es active Active
- 2017-02-02 EP EP17705745.2A patent/EP3411408B1/en active Active
- 2017-02-02 CN CN201780009313.5A patent/CN108699149B/zh active Active
- 2017-02-02 EP EP21204990.2A patent/EP4006056A1/en active Pending
- 2017-02-02 WO PCT/US2017/016300 patent/WO2017136607A1/en not_active Ceased
-
2021
- 2021-01-25 US US17/157,810 patent/US11932691B2/en active Active
- 2021-12-02 JP JP2021196080A patent/JP2022028918A/ja active Pending
-
2024
- 2024-02-07 US US18/435,933 patent/US20240352119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511904A5 (enExample) | ||
| DK2900265T3 (en) | Anti-Uroplakin II Antibodies, Systems and Methods | |
| JP6244912B2 (ja) | 癌の検出方法 | |
| EP3052522B1 (en) | Anti-sox10 antibody systems and methods | |
| CN102687011B (zh) | 癌症生物标志物及其应用 | |
| JP6244911B2 (ja) | 癌の検出方法 | |
| JP5669757B2 (ja) | 精巣癌診断および予後診断におけるｒｂｍ３タンパク質 | |
| CN105829547A (zh) | 与Wnt途径抑制剂有关的预测性生物标记物的鉴别 | |
| JP6737504B2 (ja) | 卵巣明細胞腺癌の検査方法及び検査薬 | |
| CN102472753B (zh) | 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法 | |
| CN103238069A (zh) | 肺癌和结直肠癌中的bard1同工型及其应用 | |
| US9416176B2 (en) | RBM3 protein in colorectal cancer prognostics | |
| CN105849565A (zh) | Shon作为癌症预后生物标志物并预测癌症内分泌治疗的疗效 | |
| JP7150018B2 (ja) | 新規なｃｉｐ２ａバリアント及びその使用 | |
| KR20070073802A (ko) | Ｗｎｔ 단백질 및 암의 검출 및 치료 | |
| CN101302254B (zh) | 抗肝癌源性生长因子单克隆抗体及其应用 | |
| JP2012501440A (ja) | 内分泌処置予測因子としてのａｎｌｎタンパク質 | |
| CN115667304A (zh) | 抗人lag-3抗体及其在免疫组织化学(ihc)中的用途 | |
| EP3203238A1 (en) | Reagents for detecting or diagnosing cancer cells having high invasive capacity | |
| JP6695586B2 (ja) | 膵癌の再発リスクの予測に用いるための診断薬及びキット、並びに予測方法 | |
| CN108467433B (zh) | 抗Napsin A蛋白的单克隆抗体及其细胞株、制备方法和应用 | |
| WO2020225547A1 (en) | Methods of determining the margin of a tumour | |
| US20240376227A1 (en) | ANTI-CK2a ANTIBODY OR A FRAGMENT THEREOF | |
| US20180223372A1 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| CN109021100B (zh) | 特异性识别fsd1蛋白的单克隆抗体 |